Results 211 to 220 of about 184,260 (294)

A Multicenter Survival Analysis of Adults Type B-Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World. [PDF]

Cancer Med
Sabando B, Quinonez J, Orquera A, Navarrete D, Ramírez J, Sanchez L, Chisesi T, Oliveros J, Pacheco MA, Trujillo MC, Plaza C, Lochamin R, Jimmy Martin D.   +12 more
europepmc   +1 more source

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Background B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management. Methods A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐
Zhijuan Liu, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng, Yunpeng Dai, Lian Jiang, Lirong Sun, Xiaowen Zhai, Rong Liu, Chunju Zhou, Zifen Gao, Yonghong Zhang, Xiaomei Yang   +20 more
wiley   +1 more source

Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia. [PDF]

Cancer Res Commun
Brukner I, Gagné V, Richard-St-Hilaire A, Tremblay-Dauphinais P, Fuchs C, Bittencourt H, Veres T, Sinnett D, Krajinovic M.   +8 more
europepmc   +1 more source

Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment

Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Introduction Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The pro‐drug 6‐mercaptopurine (6‐MP), essential during maintenance, is converted into active 6‐thioguanine (6‐TGN) and toxic 6‐methylmercaptopurine (6‐MMP) metabolites, resulting in marked variability in efficacy and toxicity.
Anne Ravix, Anaïs Maillat, Eva Choong, Chantal Csajka, Monia Guidi, Francesco Ceppi   +5 more
wiley   +1 more source

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, Volume 16, Issue 4, Page 803-813, April 2026.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Parent Perspectives on Physical Therapy for Their Child with Acute Lymphoblastic Leukemia: The Light at the End of the Tunnel. [PDF]

Curr Oncol
Ospina PA, Shah P, Dhaliwal L, Fisher S, Wilson BA, Pritchard L, Eisenstat DD, McNeely ML.   +7 more
europepmc   +1 more source

[Acute lymphoblastic leukemia].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1969
P, Stavem, P F, Hjort
openaire   +1 more source